CoChat

Growth inhibition of colorectal carcinoma by lentiviral TRAIL‐transgenic human mesenchymal stem cells requires their substantial intratumoral presence

Open access
Luetzkendorf, Jana, Mueller, Lutz P., Mueller, Thomas, Caysa, Henrike, Nerger, Katrin, Schmoll, Hans‐Joachim · 2010 · Journal of Cellular and Molecular Medicine
Cited by 72

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Colorectal carcinoma (CRC) constitutes a common malignancy with limited therapeutic options in metastasized stages. Mesenchymal stem cells (MSC) home to tumours and may therefore serve as a novel therapeutic tool for intratumoral delivery of antineoplastic factors. Tumour necrosis factor (TNF)‐related apoptosis inducing ligand (TRAIL) which promises apoptosis induction preferentially in tumour cells represents such a factor. We generated TRAIL‐MSC by transduction of human MSC with a third generation lentiviral vector system and analysed their characteristics and capacity to inhibit CRC growth. (1) TRAIL‐MSC showed stable transgene expression with neither changes in the defining MSC characteristics nor signs of malignant transformation. (2) Upon direct in vitro coculture TR AIL‐MSC induced apoptosis in TRAIL‐sensitive CRC‐cell lines (DLD‐1 and HCT‐15) but also in CRC‐cell lines resistant to soluble TRAIL (HCT‐8 and SW480). (3) In mixed subcutaneous (s.c.) xenografts TRAIL‐MSC inhibited CRC‐tumour growth presumably by apoptosis induction but a substantial proportion of TRAIL‐MSC within the total tumour cell number was needed to yield such anti‐tumour effect. (4) Systemic application of TRAIL‐MSC had no effect on the growth of s.c. DLD‐1 xenografts which appeared to be due to a pulmonary entrapment and low rate of tumour integration of TRAIL‐MSC. Systemic TRAIL‐MSC caused no toxicity in this model. (5) Wild‐type MSC seemed to exert a tumour growth‐supporting effect in mixed s.c. DLD‐1 xenografts. These novel results support the idea that lentiviral TRAIL‐transgenic human MSC may serve as vehicles for clinical tumour therapy but also highlight the need for further investigations to improve tumour integration of transgenic MSC and to clarify a potential tumour‐supporting effect by MSC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1582-4934.2009.00794.x

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 72

Metadata

Authors
Luetzkendorf, J., Mueller, L. P., Mueller, T., Caysa, H., Nerger, K., & Schmoll, H.
Venue
Journal of Cellular and Molecular Medicine
Publisher
Wiley
Published
2009-06-05
Volume
14
Issue
9
Pages
2292-2304
ISSN
  • 1582-1838 (ISSN-L)
  • 1582-4934
OpenAlex
W2043785981
Cited by
72
References
10
FWCI
3.04
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Growth inhibition of colorectal carcinoma by lentiviral TRAIL‐transgenic human mesenchymal stem cells requires their substantial intratumoral presence. https://app.cochat.ai/papers/10.1111/j.1582-4934.2009.00794.x
The paper
Luetzkendorf, J., Mueller, L. P., Mueller, T., Caysa, H., Nerger, K., & Schmoll, H. (2010). Growth inhibition of colorectal carcinoma by lentiviral TRAIL‐transgenic human mesenchymal stem cells requires their substantial intratumoral presence. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2009.00794.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.